YervoyMeSH concept

https://www.has-sante.fr/jcms/p_3574980/fr/opdivo-nivolumab-et-yervoy-ipilimumab-cancer-colorectal
2024
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
Ipilimumab
Nivolumab
Opdivo
ipilimumab
colorectal neoplasms
yervoy
nivolumab

---
https://www.has-sante.fr/jcms/p_3478087/fr/opdivo-yervoy-ipilimumab/nivolumab-cancer-de-l-oesophage
2023
France
evaluation of the transparency committee
Nivolumab
esophageal neoplasms
Ipilimumab
yervoy
esophagospasm
cancer of esophagus
Childhood Esophageal Carcinoma
neoplasm, malignant
Opdivo

---
https://www.has-sante.fr/jcms/p_3381119/fr/opdivo-/-yervoy-nivolumab/ipilimumab-cbnpc
2022
France
evaluation of the transparency committee
yervoy
Opdivo
carcinoma, non-small-cell lung

---
https://www.has-sante.fr/jcms/p_3290311/fr/opdivo-nivolumab-et-yervoy-ipilimumab-cancer-colorectal-metastatique
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
ipilimumab
yervoy
Opdivo
Colorectal cancer
nivolumab
colorectal neoplasms
neoplasm, malignant
Ipilimumab
Nivolumab
cancer
malignant neoplasm colon/rectum

---
https://www.has-sante.fr/jcms/p_3297497/fr/opdivo-10-mg/ml-/-yervoy-5-mg/ml-nivolumab-en-association-a-l-ipilimumab-cancer-colorectal-metastatique
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
indicators and reagents
indicators
cancer
neoplasm, malignant
ipilimumab
yervoy
Colorectal cancer
nivolumab
traction
indication of
association
colorectal neoplasms
Ipilimumab
Opdivo
Nivolumab
malignant neoplasm colon/rectum

---
https://www.has-sante.fr/jcms/p_3287835/fr/opdivo-nivolumab-et-yervoy-ipilimumab
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
yervoy
Opdivo
Ipilimumab
ipilimumab
Nivolumab
nivolumab

---
https://www.has-sante.fr/portail/jcms/c_2867431/fr/yervoy
2018
false
false
false
false
France
French
evaluation of the transparency committee
yervoy
Ipilimumab

---